<DOC>
	<DOCNO>NCT00818259</DOCNO>
	<brief_summary>This study determine appropriate dose regimen aprepitant fosaprepitant prevention chemotherapy-induced nausea vomit pediatric participant 0 month 17 year age .</brief_summary>
	<brief_title>A Study MK-0869 ( Aprepitant ) MK-0517 ( Fosaprepitant ) Pediatric Participants Receiving Chemotherapy ( MK-0869-134 )</brief_title>
	<detailed_description>Fosaprepitant prodrug aprepitant rapidly convert aprepitant intravenous administration ; pharmacological effect fosaprepitant attribute aprepitant . The birth one year old cohort initiate Parts III IV upon completion Part II ( Steps A B ) participant &lt; 6 month age .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Is 0 ( least 37 week gestation ) 17 year age Is schedule receive moderately highly nauseainducing chemotherapy participant tolerate previous chemotherapy regimen plan repeat Is expect receive ondansetron Female participant begin menstruate must negative pregnancy test Weighs ≥3.0 kg &lt; 6 month age , ≥6.0 kg &gt; 6 month age , ≥7.5 kg &gt; 2 year age Has preexist venous catheter Uses illicit drug abuse alcohol Is pregnant breast feeding Has symptomatic central nervous system ( CNS ) tumor Has infection uncontrolled disease cancer Has know history heart QT wave prolongation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>